Abstract
Heart failure (HF) and type 2 diabetes mellitus (T2DM) represent two important public health problems, and despite improvements in the management of both diseases, they are responsible for high rates of hospitalizations and mortality. T2DM accelerates physiological cardiac aging through hyperglycemia and hyperinsulinemia. Thus, HF and T2DM are chronic diseases widely represented in elderly people who often are affected by numerous comorbidities with important functional limitations making it difficult to apply the current guidelines. Several antidiabetic drugs should be used with caution in elderly individuals with T2DM. For instance, sulfonylureas should be avoided due to the risk of hypoglycemia associated with its use. Insulin should be used with caution because it is associated with higher risk of hypoglycemia, and may determine fluid retention which can lead to worsening of HF. Thiazolindinediones should be avoided due to the increased risk of fluid retention and HF. Biguanides may lead to a slightly increased risk of lactic acidosis in particular in elderly individuals with impaired renal function. Dipeptidyl peptidase 4 (DPP-4) inhibitors are safe having few side effects, minimal risk of hypoglycemia, and a neutral effect on cardiovascular (CV) outcome, even if it has been reported that saxagliptin treatment is associated with increased risk of hospitalizations for HF (hHF). Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown a CV protection without a significant reduction in hHF. On the other hand, sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown a significant improvement in CV outcome, with a strong reduction of hHF and a positive impact on renal damage progression. However, it is necessary to consider the possible some side effects related to their use in elderly individuals including hypotension, bone fractures, and ketoacidosis.
It is important to remark that elderly patients, in particular the very elderly, are not sufficiently represented in the trials; thus, the management and treatment of elderly diabetic patients with HF should be mainly based on the integration of scientific evidence with clinical judgment and patients’ condition, with respect to the dignity and quality of life.
Similar content being viewed by others
References
James SL, Abate D, Abate KH, et al (2018) Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. https://doi.org/10.1016/S0140-6736(18)32279-7
Groenewegen A, Rutten FH, Mosterd A, Hoes AW (2020) Epidemiology of heart failure. Eur J Heart Fail. https://doi.org/10.1002/ejhf.1858
van Riet EE, Hoes AW, Wagenaar KP, et al (2016) Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review. Eur J Heart Fail.https://scite.ai/reports/10.1002/ejhf.483.
Guariguata L, Whiting DR, Hambleton I et al (2014) Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. https://doi.org/10.1016/j.diabres.2013.11.002
Dunlay SM, Givertz MM, Aguilar D et al (2019) Type 2 diabetes mellitus and heart failure: a scientific statement from the american heart association and the heart failure society of america: this statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. Circulation. https://doi.org/10.1161/CIR.0000000000000691
van Melle JP, Bot M, de Jonge P et al (2010) Diabetes, glycemic control, and new-onset heart failure in patients with stable coronary artery disease: data from the heart and soul study. Diabetes Care. https://doi.org/10.2337/dc10-0286
Matsushita K, Blecker S, Pazin-Filho A et al (2010) The association of hemoglobin A1c with incident heart failure among people without diabetes: the atherosclerosis risk in communities study. Diabetes. https://doi.org/10.2337/db10-0165
Swoboda PP, McDiarmid AK, Erhayiem B et al (2017) Diabetes mellitus, microalbuminuria, and subclinical cardiac disease: identification and monitoring of individuals at risk of heart failure. J Am Heart Assoc. https://doi.org/10.1161/JAHA.117.005539
Preiss D, van Veldhuisen DJ, Sattar N et al (2012) Eplerenone and new-onset diabetes in patients with mild heart failure: results from the eplerenone in mild patients hospitalization and survival study in heart failure (EMPHASIS-HF). Eur J Heart Fail. https://doi.org/10.1093/eurjhf/hfs067
Paolillo S, Rengo G, Pellegrino T et al (2015) Insulin resistance is associated with impaired cardiac sympathetic innervation in patients with heart failure. Eur Heart J Cardiovasc Imaging. https://doi.org/10.1093/ehjci/jev061
Park JJ (2021) Epidemiology, pathophysiology, diagnosis and treatment of heart failure in diabetes. Diabetes Metab J. https://doi.org/10.4093/dmj.2020.0282
Rubler S, Dlugash J, Yuceoglu YZ et al (1972) New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol. https://doi.org/10.1016/0002-9149(72)90595-4
Marwick TH, Ritchie R, Shaw JE, Kaye D (2018) Implications of underlying mechanisms for the recognition and management of diabetic cardiomyopathy. J Am Coll Cardiol. https://doi.org/10.1016/j.jacc.2017.11.019
Petrie MC, Verma S, Docherty KF et al (2020) Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA. https://doi.org/10.1001/jama.2020.1906
Allen LA, Gheorghiade M, Reid KJ et al (2011) Identifying patients hospitalized with heart failure at risk for unfavorable future quality of life. Circ Cardiovasc Qual Outcomes. https://doi.org/10.1161/CIRCOUTCOMES.110.958009
Targher G, Dauriz M, Laroche C et al (2017) In-hospital and 1-year mortality associated with diabetes in patients with acute heart failure: results from the ESC-HFA heart failure long-term registry. Eur J Heart Fail. https://doi.org/10.1002/ejhf.679
Dauriz M, Targher G, Laroche C et al (2017) Association between diabetes and 1-year adverse clinical outcomes in a multinational cohort of ambulatory patients with chronic heart failure: results from the ESC-HFA heart failure long-term registry. Diabetes Care. https://doi.org/10.2337/dc16-0574
MacDonald MR, Petrie MC, Varyani F et al 2008. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. Eur Heart J. https://doi.org/10.1093/eurheartj/ehn153
Kristensen SL, Mogensen UM, Jhund PS et al (2017) Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: a report from the I-PRESERVE trial (irbesartan in heart failure with preserved ejection fraction). Circulation. https://doi.org/10.1161/CIRCULATIONAHA.116.024593
Lawson CA, Jones PW, Teece L et al (2018) Association between type 2 diabetes and all-cause hospitalization and mortality in the UK general heart failure population: stratification by diabetic glycemic control and medication intensification. JACC Heart Fail. https://doi.org/10.1016/j.jchf.2017.08.020
Triposkiadis F, Xanthopoulos A, Butler J (2019) Cardiovascular aging and heart failure: JACC review topic of the week. J Am Coll Cardiol. 2019. https://doi.org/10.1016/j.jacc.2019.06.053
Hanon O, Belmin J, Benetos A et al (2021) Consensus of experts from the french society of geriatrics and gerontology on the management of heart failure in very old subjects. Arch Cardiovasc Dis. https://doi.org/10.1016/j.acvd.2020.12.001
Strain WD, Down S, Brown P et al (2021) Diabetes and frailty: an expert consensus statement on the management of older adults with type 2 diabetes. Diabetes Ther. https://doi.org/10.1007/s13300-021-01035-9
Kalra S, Sharma SK (2018) Diabetes in the elderly. Diabetes Ther. https://doi.org/10.1007/s13300-018-0380-x
Parker SG, McLeod A, McCue P et al (2017) New horizons in comprehensive geriatric assessment. Age Ageing. https://doi.org/10.1093/ageing/afx104
Clegg A, Young J, Iliffe S et al (2013) Frailty in elderly people. Lancet. https://doi.org/10.1016/S0140-6736(12)62167-9
Clegg A, Bates C, Young J et al (2016) Development and validation of an electronic frailty index using routine primary care electronic health record data. Age Ageing. https://doi.org/10.1093/ageing/afw039
Pandey A, Kitzman D, Reeves G (2019) Frailty is intertwined with heart failure: mechanisms, prevalence, prognosis, assessment, and management. JACC Heart Fail. https://doi.org/10.1016/j.jchf.2019.10.005
Ponikowski P, Voors AA, Anker SD et al (2016) ESC scientific document group. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the european society of cardiology (ESC) developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J. https://doi.org/10.1093/eurheartj/ehw128
Biessels GJ, Despa F (2018) Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications. Nat Rev Endocrinol. https://doi.org/10.1038/s41574-018-0048-7
Trachanas K, Sideris S, Aggeli C et al (2014) Diabetic cardiomyopathy: from pathophysiology to treatment. Hell J Cardiol 55:411–421
Ahmed SS, Jafer GA, Narang RM et al (1975) Preclinical abnormality of left ventricular function in diabetes mellitus. Am Heart J. https://doi.org/10.1016/0002-8703(75)90039-3
Wang J, Song Y, Wang Q et al (2006) Causes and characteristics of diabetic cardiomyopathy. Rev Diabet Stud. https://doi.org/10.1900/RDS.2006.3.108
Kurt M, Wang J, Torre-Amione G et al (2009) Left atrial function in diastolic heart failure. Circ Cardiovasc Imaging. https://doi.org/10.1161/CIRCIMAGING.108.813071
Lamberts RR, Lingam SJ, Wang HY et al (2014) Impaired relaxation despite upregulated calcium-handling protein atrial myocardium from type 2 diabetic patients with preserved ejection fraction. Cardiovasc Diabetol. https://doi.org/10.1186/1475-2840-13-72
Otake H, Suzuki H, Honda T, Maruyama Y (2009) Influences of autonomic nervous system on atrial arrhythmogenic substrates and the incidence of atrial fibrillation in diabetic heart. Int Heart J. https://doi.org/10.1536/ihj.50.627
Cameli M, Lisi M, Focardi M et al (2012) Left atrial deformation analysis by speckle tracking echocardiography for prediction of cardiovascular outcomes. Am J Cardiol. https://doi.org/10.1016/j.amjcard.2012.03.022
Liu JH, Chen Y, Yuen M et al (2016) Incremental prognostic value of global longitudinal strain in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. https://doi.org/10.1016/j.amjcard.2012.03.022
Tadic M, Cuspidi C, Vukomanovic V et al (2018) Layer-specific deformation of the left ventricle in uncomplicated patients with type 2 diabetes and arterial hypertension. Arch Cardiovasc Dis. https://doi.org/10.1016/j.acvd.2017.01.014
Abou R, Leung M, Khidir MJH et al (2017) Influence of aging on level and layer-specifc left ventricular longitudinal strain in subjects without structural heart disease. Am J Cardiol. https://doi.org/10.1016/j.amjcard.2017.08.027
Sciacqua A, Perticone M, Miceli S et al (2019) Elevated 1-h post-load plasma glucose is associated with right ventricular morphofunctional parameters in hypertensive patients. Endocrine 64. https://doi.org/10.1007/s12020-019-01873-5
Lee YC, Chang CH, Dong YH et al (2017) Comparing the risks of hospitalized heart failure associated with glinide, sulfonylurea, and acarbose use in type 2 diabetes: a nationwide study. Int J Cardiol. https://doi.org/10.1016/j.ijcard.2016.11.022
American Diabetes Association (2021) Older adults: standards of medical care in diabetes. Diabetes Care. https://doi.org/10.2337/dc21-S012
LeRoith D, Jan Biessels G, Braithwaite SB et al (2019) Treatment of diabetes in older adults: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. https://doi.org/10.1210/jc.2019-00198
American Geriatrics Society (2019) Updated AGS beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. https://doi.org/10.1111/jgs.15767
Zoungas S, Patel A, Chalmers J et al (2010) Severe hypoglycemia and risks of vascular events and death. N Engl J Med. https://doi.org/10.1056/NEJMoa1003795
Dargie HJ, Hildebrandt PR, Riegger GA et al (2007) A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with new york heart association functional class I or II heart failure. J Am Coll Cardiol. https://doi.org/10.1016/j.jacc.2006.10.077
Eurich DT, Weir DL, Majumdar SR et al (2013) Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail. https://doi.org/10.1161/CIRCHEARTFAILURE.112.000162
Pratley RE, Husain M, Lingvay I et al (2019) Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14. Cardiovasc Diabetol. https://doi.org/10.1186/s12933-019-0960-8
Gerstein HC, Bosch J, Dagenais GR et al (2012) Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. https://doi.org/10.1056/NEJMoa1203858
Cosmi F, Shen L, Magnoli M et al (2018) Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes. Eur J Heart Fail. https://doi.org/10.1002/ejhf.1146
Dunlay SM, Givertz MM, Aguilar D et al (2019) Type 2 diabetes mellitus and heart failure: a scientific statement from the american heart association and the heart failure society of america: this statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. Circulation. https://doi.org/10.1161/CIR.0000000000000691
Scirica BM, Bhatt DL, Braunwald E et al (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. https://doi.org/10.1056/NEJMoa1307684
Leiter LA, Teoh H, Braunwald E et al (2015) Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial. Diabetes Care. https://doi.org/10.2337/dc14-2868
Green JB, Bethel MA, Armstrong PW et al (2015) Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. https://doi.org/10.1056/NEJMoa1501352
Bethel MA, Engel SE, Green JB et al (2017) Assessing the safety of sitagliptin in older participants in the trial evaluating cardiovascular outcomes with sitagliptin (TECOS). Diabetes Care. https://doi.org/10.2337/dc16-1135
White WB, Cannon CP, Heller SR et al (2015) Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. https://doi.org/10.1056/NEJMoa1305889
Zannad F, Cannon CP, Cushman WC et al (2015) Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. https://doi.org/10.1016/S0140-6736(14)62225-X
Rosenstock J, Perkovic V, Johansen OE et al (2019) Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. https://doi.org/10.1001/jama.2018.18269
Cooper ME, Rosenstock J, Kadowaki T et al (2020) Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and/or kidney disease: a prespecified subgroup analysis of the randomized, placebo-controlled CARMELINA trial. Diabetes Obes Metab. https://doi.org/10.1111/DOM.13995
Rosenstock J, Kahn SE, Johansen OE et al (2019) Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA. https://doi.org/10.1001/jama.2019.13772
Espeland MA, Pratley RE, Rosenstock J et al (2021) Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: a subgroup analysis of the randomized CAROLINA trial. Diabetes Obes Metab.https://doi.org/10.1111/dom.14254
Ledesma G, Umpierrez GE, Morley JE et al (2019) Efficacy and safety of linagliptin to improve glucose control in older people with type 2 diabetes on stable insulin therapy: a randomized trial. Diabetes Obes Metab. https://doi.org/10.1111/DOM.13829
Shen J, Greenberg BH (2021) Diabetes management in patients with heart failure. Diabetes Metab J. https://doi.org/10.4093/dmj.2020.0296
Zheng SL, Roddick AJ, Aghar-Jaffar R et al (2018) Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis. JAMA. https://doi.org/10.1001/jama.2018.3024
Freeman J (2019) Management of hypoglycemia in older adults with type 2 diabetes. Postgrad Med. https://doi.org/10.1080/00325481.2019.1578590
Dave CV, Schneeweiss S, Wexler DJ et al (2020) Trends in clinical characteristics and prescribing preferences for SGLT2 inhibitors and GLP-1 receptor agonists, 2013–2018. Diabetes Care. https://doi.org/10.2337/dc19-1943
Herrera Comoglio R, Vidal Guitart X (2020) Cardiovascular outcomes, heart failure and mortality in type 2 diabetic patients treated with glucagon-like peptide 1 receptor agonists (GLP-1 RAs): a systematic review and meta-analysis of observational cohort studies. Int J Clin Pract. https://doi.org/10.1111/ijcp.13553
North EJ, Newman JD (2019) Review of cardiovascular outcomes trials of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists. Curr Opin Cardiol. https://doi.org/10.1097/HCO.0000000000000673
Marsico F, Paolillo S, Gargiulo P et al (2020) Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials. Eur Heart J. https://doi.org/10.1093/eurheartj/ehaa082
Karagiannis T, Tsapas A, Athanasiadou E et al (2021) GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract. https://doi.org/10.1016/j.diabres.2021.108737
Pfeffer MA, Claggett B, Diaz R et al (2015) Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. https://doi.org/10.1056/NEJMoa1509225
Marso SP, Daniels GH, Brown-Frandsen K et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. https://doi.org/10.1056/NEJMoa1603827
Marso SP, Bain SC, Consoli A et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. https://www.nejm.org/doi/full/10.1056/NEJMoa1607141
Holman RR, Bethel MA, Mentz RJ et al (2017) Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. https://doi.org/10.1056/NEJMoa161291
Hernandez AF, Green JB, Janmohamed S et al (2018) Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (harmony outcomes): a double-blind, randomised placebo-controlled trial. Lancet. https://doi.org/10.1016/S0140-6736(18)32261-X
Gerstein HC, Colhoun HM, Dagenais GR et al (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. https://doi.org/10.1016/S0140-6736(19)31149-3
Margulies KB, Hernandez AF, Redfield MM et al (2016) NHLBI heart failure clinical research network. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 316(5):500–508
Longato E, Di Camillo B, Sparacino G et al (2020) Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice. Cardiovasc Diabetol. https://doi.org/10.1186/s12933-020-01049-w
Longato E, Di Camillo B, Sparacino G et al (2020) Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life. BMJ Open Diabetes Res Care. https://doi.org/10.1136/bmjdrc-2020-001451
Longato E, Di Camillo B, Sparacino G et al (2021) Cardiovascular effectiveness of human-based vs. exendin-based glucagon like peptide-1 receptor agonists: a retrospective study in patients with type 2 diabetes. Eur J Prev Cardiol.https://doi.org/10.1093/eurjpc/zwaa081
Trevisan M, Fu EL, Szummer K et al (2021) Glucagon-like peptide-1 receptor agonists and the risk of cardiovascular events in diabetes patients surviving an acute myocardial infarction. Eur Heart J Cardiovasc Pharmacother. https://doi.org/10.1093/ehjcvp/pvaa004
Seferovic PM, Coats AJS, Ponikowski P et al (2020) European society of cardiology/heart failure association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure. Eur J Heart Fail. https://doi.org/10.1002/ejhf.1673
Lytvyn Y, Bjornstad P, Udell JA, Lovshin JA, Cherney DZI (2017) Sodium glucose cotransporter-2 inhibition in heart failure. Circulation. https://doi.org/10.1161
Butler J, Usman MS, Khan MS et al (2020) Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis. ESC Heart Failure. https://doi.org/10.1002/ehf2.13169
Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. https://doi.org/10.1056/NEJMoa1504720
Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. https://doi.org/10.1056/NEJMoa1611925
Rådholm K, Figtree G, Perkovic V et al (2018) Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS program. Circulation. https://doi.org/10.1161/CIRCULATIONAHA.118.034222
Wiviott SD, Raz I, Bonaca MP et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. https://doi.org/10.1056/NEJMoa1812389
Cahn A, Mosenzon O, Wiviott SD et al (2020) Efficacy and safety of dapagliflozin in the elderly: analysis from the DECLARE–TIMI 58 study. Diabetes Care 2020. https://doi.org/10.2337/dc19-1476
Cannon CP, Pratley R, Dagogo-Jack S et al (2020) Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. https://doi.org/10.1056/NEJMoa2004967
Cosentino F, Cannon CP, Cherney DZI et al (2020) Efficacy of ertugliflozin on heart failure–related events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease. Circulation. https://doi.org/10.1161/CIRCULATIONAHA.120.050255
Bhatt DL, Szarek M, Steg PG et al (2021) Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. https://doi.org/10.1056/NEJMoa2030183
Lam CSP, Karasik A, Melzer-Cohen C et al (2021) Association of sodium-glucose cotransporter-2 inhibitors with outcomes in type 2 diabetes with reduced and preserved left ventricular ejection fraction: analysis from the CVD-REAL 2 study. Diabetes Obes Metab. https://doi.org/10.1111/dom.14356
McMurray JJV, Solomon SD, Inzucchi SE et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. https://doi.org/10.1056/NEJMoa1911303
Martinez FA, Serenelli M, Nicolau JC et al (2019) Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to age. Circulation. https://doi.org/10.1161/CIRCULATIONAHA.119.044133
Nassif ME, Qintar M, Windsor SL et al (2021) Empagliflozin effects on pulmonary artery pressure in patients with heart failure. Circulation. https://doi.org/10.1161/CIRCULATIONAHA.120.052503
Packer M, Anker SD, Butler J et al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. https://doi.org/10.1056/NEJMoa2022190
Zannad F, Ferreira JP, Pocock SJ et al (2020) SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-reduced and DAPA-HF trials. Lancet. https://doi.org/10.1016/S0140-6736(20)31824-9
Heerspink HJL, Perkins BA, Fitchett DH et al (2016) Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus. Circulation. https://doi.org/10.1161/CIRCULATIONAHA.116.021887
Kuchay MS, Krishan S, Mishra SK et al (2018) Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial). Diabetes Care. https://doi.org/10.2337/dc18-0165
Santos-Gallego CG, Requena-Ibanez JA, San Antonio R et al (2019) Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics. J Am Coll Cardiol. https://doi.org/10.1016/j.jacc.2019.01.056
Uthman L, Baartsceer A, Bleijlevens B et al (2018) Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation. Diabetologia. https://doi.org/10.1007/s00125-017-4509-7
Seferović PM, Coats AJS, Ponikowski P et al (2020) European society of cardiology/heart failure association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure. Eur J Heart Fail. https://doi.org/10.1002/ejhf.1673
Sesti G, Incalzi RA, Bonora E et al (2018) Management of diabetes in older adults. Nutr Metab Cardiovasc Dis. https://doi.org/10.1016/j.numecd.2017.11.007
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Sciacqua, A., Succurro, E., Armentaro, G. et al. Pharmacological treatment of type 2 diabetes in elderly patients with heart failure: randomized trials and beyond. Heart Fail Rev 28, 667–681 (2023). https://doi.org/10.1007/s10741-021-10182-x
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10741-021-10182-x